Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
    Most visited pages

        GUERBET MEDICAL IMAGING R&D

        Signature(s)

        Amount
        € 40,000,000
        Countries
        Sector(s)
        France : € 40,000,000
        Industry : € 40,000,000
        Signature date(s)
        25/03/2009 : € 40,000,000

        Summary sheet

        Release date
        24 September 2008
        Status
        Reference
        Signed | 25/03/2009
        20080368
        Project name
        Promoter - financial intermediary
        Guerbet Medical Imaging R&D

        Guerbet S.A.

        Proposed EIB finance (Approximate amount)
        Total cost (Approximate amount)
        Up to EUR 40 million.
        Estimated at around EUR 90 million.
        Location
        Sector(s)
        Description
        Objectives

        The project focuses on the development of new or improved contrast agents for medical imaging. If successful, they will improve the anatomic visualisation of human organs, the detection of pathologies as well as the functional evaluation of certain organs.

        The project helps to strengthen the knowledge base and, by default, the market position of a European specialist pharmaceutical company that operates in the segmented global market for medical imaging. Furthermore, the project is expected to increase the small number of contrast agents that are currently on the market.

        Environmental aspects
        Procurement

        The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres etc. An EIA required by EU Directive 97/11 as amended by Directive 2003/35 is therefore not required. Compliance of R&D activities with relevant EU environmental legislation will be verified during appraisal.

        The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU directives on procurement.

        Disclaimer

        Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
        They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

        General enquiries and comments

        The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
        Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
        Alternatively, the EIB can be contacted through its external offices.
        Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

        Media enquiries

        Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

        Complaints mechanism

        Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

        Zero tolerance against fraud and corruption

        The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

        Related publications